값202020212022202320242025TTM판매비·일반관리비———————연구개발———————영업 이익———————비영업 수익, 합계———————이자비용(자본화한 이자 차감 후)———————이자비용을 제외한 비영업 수익———————비정상 수입/지출———————세전소득———————지분법 손익———————세금———————비지배 지분———————세후 기타 수익/비용———————중단된 사업 부문 제외 순이익———————중단된 사업———————순이익———————희석보정———————우선배당———————보통주주에게 귀속되는 희석 순이익———————주당 순이익(기본 EPS)———————희석 주당 순이익 (희석 EPS)———————평균 발행주식수———————희석주식수———————EBITDA———————EBIT———————매출원가———————기타 매출원가———————감가상각 및 무형자산 상각 (현금흐름)———————
BioNTech SE - American Depositary Shares
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic.